431 related articles for article (PubMed ID: 17332359)
21. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene.
Xu M; Li D; Lu Y; Chen GQ
Exp Hematol; 2007 Aug; 35(8):1249-55. PubMed ID: 17560011
[TBL] [Abstract][Full Text] [Related]
22. A TAF4-homology domain from the corepressor ETO is a docking platform for positive and negative regulators of transcription.
Wei Y; Liu S; Lausen J; Woodrell C; Cho S; Biris N; Kobayashi N; Wei Y; Yokoyama S; Werner MH
Nat Struct Mol Biol; 2007 Jul; 14(7):653-61. PubMed ID: 17572682
[TBL] [Abstract][Full Text] [Related]
23. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
Peterson LF; Lo MC; Okumura AJ; Zhang DE
Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
[TBL] [Abstract][Full Text] [Related]
24. Biophysical and pharmacokinetic characterization of a small-molecule inhibitor of RUNX1/ETO tetramerization with anti-leukemic effects.
Gopalswamy M; Kroeger T; Bickel D; Frieg B; Akter S; Schott-Verdugo S; Viegas A; Pauly T; Mayer M; Przibilla J; Reiners J; Nagel-Steger L; Smits SHJ; Groth G; Etzkorn M; Gohlke H
Sci Rep; 2022 Aug; 12(1):14158. PubMed ID: 35986043
[TBL] [Abstract][Full Text] [Related]
25. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.
Licht JD
Oncogene; 2001 Sep; 20(40):5660-79. PubMed ID: 11607817
[No Abstract] [Full Text] [Related]
26. Interference with RUNX1/ETO leukemogenic function by cell-penetrating peptides targeting the NHR2 oligomerization domain.
Bartel Y; Grez M; Wichmann C
Biomed Res Int; 2013; 2013():297692. PubMed ID: 23865046
[TBL] [Abstract][Full Text] [Related]
27. Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity.
Lu Y; Peng ZG; Yuan TT; Yin QQ; Xia L; Chen GQ
Leukemia; 2008 Feb; 22(2):378-86. PubMed ID: 17989718
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein.
Fazi F; Racanicchi S; Zardo G; Starnes LM; Mancini M; Travaglini L; Diverio D; Ammatuna E; Cimino G; Lo-Coco F; Grignani F; Nervi C
Cancer Cell; 2007 Nov; 12(5):457-66. PubMed ID: 17996649
[TBL] [Abstract][Full Text] [Related]
29. Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.
Chen-Wichmann L; Shvartsman M; Preiss C; Hockings C; Windisch R; Redondo Monte E; Leubolt G; Spiekermann K; Lausen J; Brendel C; Grez M; Greif PA; Wichmann C
Oncogene; 2019 Jan; 38(2):261-272. PubMed ID: 30093631
[TBL] [Abstract][Full Text] [Related]
30. LPXN, a member of the paxillin superfamily, is fused to RUNX1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation.
Dai HP; Xue YQ; Zhou JW; Li AP; Wu YF; Pan JL; Wang Y; Zhang J
Genes Chromosomes Cancer; 2009 Dec; 48(12):1027-36. PubMed ID: 19760607
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic regulation of tumor suppressors in t(8:21)-containing AML.
Yang G; Khalaf W; van de Locht L; Jansen JH; van der Reijden BA; Müller-Tidow C; Delwel HR; Serve H; Clapp DW; Hiebert SW
Ann Hematol; 2004 Jun; 83(6):329-30. PubMed ID: 15052372
[TBL] [Abstract][Full Text] [Related]
32. Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1.
Li X; Vradii D; Gutierrez S; Lian JB; van Wijnen AJ; Stein JL; Stein GS; Javed A
J Cell Biochem; 2005 Nov; 96(4):795-809. PubMed ID: 16149049
[TBL] [Abstract][Full Text] [Related]
33. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells.
Nimer SD; Moore MA
Oncogene; 2004 May; 23(24):4249-54. PubMed ID: 15156180
[TBL] [Abstract][Full Text] [Related]
34. Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22).
Sakai I; Tamura T; Narumi H; Uchida N; Yakushijin Y; Hato T; Fujita S; Yasukawa M
Genes Chromosomes Cancer; 2005 Nov; 44(3):265-70. PubMed ID: 16015645
[TBL] [Abstract][Full Text] [Related]
35. Domains involved in ETO and human N-CoR interaction and ETO transcription repression.
Wang J; Wang M; Liu JM
Leuk Res; 2004 Apr; 28(4):409-14. PubMed ID: 15109542
[TBL] [Abstract][Full Text] [Related]
36. The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16; 21)-positive myeloid malignancies.
Hoogeveen AT; Rossetti S; Stoyanova V; Schonkeren J; Fenaroli A; Schiaffonati L; van Unen L; Sacchi N
Oncogene; 2002 Sep; 21(43):6703-12. PubMed ID: 12242670
[TBL] [Abstract][Full Text] [Related]
37. NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells.
Hackanson B; Abdelkarim M; Jansen JH; Lübbert M
Leukemia; 2010 Apr; 24(4):860-1. PubMed ID: 20090777
[No Abstract] [Full Text] [Related]
38. Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells.
Racanicchi S; Maccherani C; Liberatore C; Billi M; Gelmetti V; Panigada M; Rizzo G; Nervi C; Grignani F
EMBO J; 2005 Mar; 24(6):1232-42. PubMed ID: 15729358
[TBL] [Abstract][Full Text] [Related]
39. Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.
Wichmann C; Becker Y; Chen-Wichmann L; Vogel V; Vojtkova A; Herglotz J; Moore S; Koch J; Lausen J; Mäntele W; Gohlke H; Grez M
Blood; 2010 Jul; 116(4):603-13. PubMed ID: 20430957
[TBL] [Abstract][Full Text] [Related]
40. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
Wang J; Saunthararajah Y; Redner RL; Liu JM
Cancer Res; 1999 Jun; 59(12):2766-9. PubMed ID: 10383127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
